NO993868L - 3-piperidyl-4-oksokinazolinderivater og farmasöytiske preparater omfattende samme - Google Patents

3-piperidyl-4-oksokinazolinderivater og farmasöytiske preparater omfattende samme

Info

Publication number
NO993868L
NO993868L NO993868A NO993868A NO993868L NO 993868 L NO993868 L NO 993868L NO 993868 A NO993868 A NO 993868A NO 993868 A NO993868 A NO 993868A NO 993868 L NO993868 L NO 993868L
Authority
NO
Norway
Prior art keywords
compounds
piperidyl
group
ldl
substituted
Prior art date
Application number
NO993868A
Other languages
English (en)
Other versions
NO993868D0 (no
Inventor
Motohide Sato
Takeo Katsushima
Hajime Kinoshita
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of NO993868D0 publication Critical patent/NO993868D0/no
Publication of NO993868L publication Critical patent/NO993868L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

3-piperidyl-4-oksokinazolin- derivater representert ved formelen d): hvor R representerer en aminogruppe eller en syklisk aminogruppe, så som dibenzoazepin, hvor hver er substituert med en substituert eller usubstituert arylgruppe, heteroarylgruppe eller lig- nende; n er et helt tall fra l til 4; R3 og R4 representerer uavhengig av hverandre et hydrogenatom, en lavere alkylgruppe eller lignende eller et farmasøytisk akseptabelt salt derav. Forbindelsene (I) har utmerket WfP- inhiberende aktivitet. Disse forbind- elser inhiberer ikke bare dannelse av LDL som er en årsak til arteriosklerot- iske sykdommer, men regulerer også TG, kolesterol og lipoproteiner, som LDL i blodet, og regulerer lipider i cellene gjennom regulering av MTP-aktiviteten. Forbindelsene kan også anvendes som preventive eller terapeutiske midler for hyperlipemi eller arteriosklerot- iske sykdommer. Dessuten kan det an- vendes som terapeutiske eller preven- tive midler for pankreatitt, overvekt, hyperkolesterolemi og hypertriglyserid-
NO993868A 1997-12-12 1999-08-11 3-piperidyl-4-oksokinazolinderivater og farmasöytiske preparater omfattende samme NO993868L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP36281997 1997-12-12
JP10288979A JP2959765B2 (ja) 1997-12-12 1998-10-12 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
PCT/JP1998/005628 WO1999031085A1 (fr) 1997-12-12 1998-12-11 Derives du 3-piperidyl-4-oxoquinazoline et compositions medicinales les contenant

Publications (2)

Publication Number Publication Date
NO993868D0 NO993868D0 (no) 1999-08-11
NO993868L true NO993868L (no) 1999-10-12

Family

ID=26557408

Family Applications (1)

Application Number Title Priority Date Filing Date
NO993868A NO993868L (no) 1997-12-12 1999-08-11 3-piperidyl-4-oksokinazolinderivater og farmasöytiske preparater omfattende samme

Country Status (18)

Country Link
US (1) US6235730B1 (no)
EP (1) EP0970954A4 (no)
JP (1) JP2959765B2 (no)
KR (1) KR20000070983A (no)
CN (1) CN1252068A (no)
AR (1) AR009212A1 (no)
AU (1) AU717963B2 (no)
BR (1) BR9807339A (no)
CA (1) CA2280705A1 (no)
HU (1) HUP0001154A3 (no)
ID (1) ID23439A (no)
IL (1) IL131319A0 (no)
NO (1) NO993868L (no)
NZ (1) NZ337118A (no)
PE (1) PE20000054A1 (no)
SK (1) SK109399A3 (no)
TR (1) TR199901933T1 (no)
WO (1) WO1999031085A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767739B2 (en) 2001-07-30 2004-07-27 Isis Pharmaceuticals Inc. Antisense modulation of microsomal triglyceride transfer protein expression
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
USPP12295P2 (en) * 1999-06-01 2001-12-18 Florfis Ag Geranium plant named ‘Fiscoral’
US6258819B1 (en) * 1999-08-05 2001-07-10 Syntex (U.S.A.) Llc Substituted 2(4-piperidyl)-4(3H)-quinazolinones and 2-(4-piperidyl)-4(3H)-azaquinazolinones
JP2003104971A (ja) * 1999-08-12 2003-04-09 Wakunaga Pharmaceut Co Ltd 新規アニリド誘導体又はその塩及びこれを含有する医薬
WO2001056990A2 (en) * 2000-02-03 2001-08-09 Eli Lilly And Company Pyridine derivates as potentiators of glutamate receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
EP1404653B1 (en) * 2001-06-28 2008-08-20 Pfizer Products Inc. Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion
BR0306292A (pt) 2002-02-28 2004-08-24 Japan Tobacco Inc Composto de éster e uso medicinal do mesmo
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
EP1603450A4 (en) 2003-03-07 2009-07-29 Univ Columbia METHODS USING TYPE 1 RYANODINE RECEPTOR
WO2005021486A1 (ja) 2003-08-29 2005-03-10 Japan Tobacco Inc. エステル誘導体及びその医薬用途
JP4773969B2 (ja) * 2003-10-08 2011-09-14 イーライ リリー アンド カンパニー 脂質代謝異常の治療ための化合物及び方法
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7417040B2 (en) * 2004-03-01 2008-08-26 Bristol-Myers Squibb Company Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7378426B2 (en) * 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
US8101774B2 (en) 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
KR20070072888A (ko) * 2004-10-25 2007-07-06 니뽄 다바코 산교 가부시키가이샤 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법
EP1890767A2 (en) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2007056388A2 (en) * 2005-11-07 2007-05-18 The General Hospital Corporation Compositions and methods for modulating poly (adp-ribose) polymerase activity
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
AU2007303846B2 (en) * 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
US8735391B2 (en) 2008-09-26 2014-05-27 University Of Kansas Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods
US9040533B2 (en) 2012-12-27 2015-05-26 Purdue Pharma L.P. Oxime-substituted-quinoxaline-type piperidine compounds as ORL-1 modulators
AU2017311691B2 (en) * 2016-08-18 2021-12-02 Vidac Pharma Ltd. Piperazine derivatives, pharmaceutical compositions and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1583753A (en) * 1976-07-14 1981-02-04 Science Union & Cie Piperidine derivatives processes for their preparation and pharmaceutical compositions containing them
US4292321A (en) 1979-05-24 1981-09-29 Warner-Lambert Company 1,3,8-Triazaspirodecane-4-ones, pharmaceutical compositions thereof and method of use thereof
US4364954A (en) 1980-01-10 1982-12-21 Warner-Lambert Company Diphenylpropanamines, compositions thereof and use thereof
ZA931601B (en) 1992-03-06 1993-10-05 Squibb & Sons Inc Microsomal triglyceride transfer protein
US5595872A (en) 1992-03-06 1997-01-21 Bristol-Myers Squibb Company Nucleic acids encoding microsomal trigyceride transfer protein
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
JPH08151377A (ja) 1994-11-25 1996-06-11 Kyowa Hakko Kogyo Co Ltd キナゾリン誘導体
US5919795A (en) 1995-06-07 1999-07-06 Pfizer Inc. Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and their use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (Apo B) secretion
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide

Also Published As

Publication number Publication date
AR009212A1 (es) 2000-04-12
AU1506899A (en) 1999-07-05
US6235730B1 (en) 2001-05-22
SK109399A3 (en) 2000-01-18
AU717963B2 (en) 2000-04-06
PE20000054A1 (es) 2000-02-09
HUP0001154A3 (en) 2001-06-28
JP2959765B2 (ja) 1999-10-06
BR9807339A (pt) 2000-03-21
EP0970954A4 (en) 2001-01-10
KR20000070983A (ko) 2000-11-25
ID23439A (id) 2000-04-20
EP0970954A1 (en) 2000-01-12
NO993868D0 (no) 1999-08-11
TR199901933T1 (xx) 2000-03-21
WO1999031085A1 (fr) 1999-06-24
IL131319A0 (en) 2001-01-28
NZ337118A (en) 2000-03-27
HUP0001154A2 (hu) 2001-04-28
CA2280705A1 (en) 1999-06-24
JPH11228569A (ja) 1999-08-24
CN1252068A (zh) 2000-05-03

Similar Documents

Publication Publication Date Title
NO993868L (no) 3-piperidyl-4-oksokinazolinderivater og farmasöytiske preparater omfattende samme
TR200202200T2 (tr) Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler.
Rubino et al. Biphenyl sulfonylamino methyl bisphosphonic acids as inhibitors of matrix metalloproteinases and bone resorption
NO20014225L (no) Nye sykliske tetrapeptid-derivater og anvendelse av dem som legemidler
TW200800988A (en) Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
NO20074310L (no) Spiroketalderivat og anvendelse derav som diabetesmedisin
EP1258252A4 (en) INHIBITORS OF INTEGRINEXPRESSION
NO20051411L (no) Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav
NO20054331L (no) Substituerte-8-perfluoralkyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on-derivater
EP1736467A4 (en) NEW SULFONIC ACID AMID DERIVATIVE
NO20065573L (no) Orto-substituerte aryl eller heteroarylamidforbindelser
NO20052802L (no) Pyrrolopyrimidinderivativer
DK0870765T3 (da) Aminothiazolderivat, lægemiddel indeholdende samme og mellemprodukt til fremstilling af forbindelsen
DK0874812T3 (da) Hidtil ukendte 2,3,5-trimethyl-4-hydroxyanilidderivater, fremstilling deraf og terapeutisk anvendelse deraf
NO20055921L (no) Heterocykliske metylsulfonderivater
NO973635L (no) Fremgangsmåte for hemming av celle-celle adhesjon
RS49906B (sr) Benzociklohepteni, postupak za njihovo dobijanje, farmaceutski preparati koji ove sadrže kao i njihova primena za izradu lekova
AU4396899A (en) Remedies for diabetes
DE50011034D1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ES2011427T3 (es) Derivados de la oxima de octahidronaftaleno para la inhibicion de la sintesis del colesterol, procedimientos para su preparacion y composiciones que los contienen.
DE69814800D1 (de) Epoxysuccinamid-derivate oder ihre salze
EA200000389A3 (ru) Новые замещенные пиридины или пиперидины, способ их получения и содержащие их фармацевтические композиции
WO2001079170A3 (en) Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
HUP0202647A2 (hu) Új arilalkanoilszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
NO992316L (no) Benzensulfonamidderivater og legemidler inneholdende disse

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application